Natalizumab efficacy on cognitive impairment in MS.
We report follow-up data on the efficacy of natalizumab therapy on neuropsychological impairment on an italian MS group of 39 patients at 1 year and of 11 patients at 2 years. Results show a significant reduction in relapse rate, in the number of impaired neuropsychological tests as well as in several single executive function and reasoning tests scores at 1 year. Improvement persisted at 2 years, including also memory and speed processing tasks. These data support the efficacy of natalizumab therapy in all the clinical domains, including cognitive deterioration, in multiple sclerosis patients.
Mattioli
F
F
Neuropsychology Unit, Spedali Civili of Brescia, Via Nikolajewka, 13, 25123, Brescia, Italy. flaviacaterina.mattioli@gmail.com
Stampatori
C
C
Bellomi
F
F
Capra
R
R
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D000069442:Natalizumab; D009483:Neuropsychological Tests; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab